Key clinical trials of filgotinib
| Drug(s) | Indication | Phase | Status | Location(s) | Identifier | Sponsor |
|---|---|---|---|---|---|---|
| Filgotinib, adalimumab, placebo, methotrexate | RA | 3 | Completed | International |
FINCH 1; NCT02889796; GS-US-417-0301; 2016-000568-41 |
Gilead Sciences |
| Filgotinib, placebo, csDMARDs | RA | 3 | Completed | International |
FINCH 2; NCT02873936; GS-US-417-0302; 2016-000569-21 |
Gilead Sciences |
| Filgotinib, placebo, methotrexate | RA | 3 | Completed | International |
FINCH 3; NCT02886728; GS-US-417-0303; 2016-000570-37 |
Gilead Sciences |
| Filgotinib, placebo | RA | 3 | Ongoing | International |
FINCH 4; NCT03025308; GS-US-417-0304; 2016-003630-25 |
Gilead Sciences |
| Filgotinib, placebo | RA | 2b | Completed | International |
DARWIN 1; NCT01888874; GLPG0634-CL-203; 2012-003635-31 |
Galapagos NV |
| Filgotinib, placebo | RA | 2 | Completed | International |
DARWIN 2; NCT01894516; GLPG0634-CL-204 |
Galapagos NV |
| Filgotinib | RA | 2 | Ongoing | International |
DARWIN 3; NCT02065700; GLPG0634-CL-205; 2012-003655-11 |
Gilead Sciences |
| Filgotinib, placebo | RA | 2 | Completed | International | NCT01668641; GLPG0634-CL-202 | Galapagos NV |
| Filgotinib | RA | 2 | Completed | Republic of Moldova | NCT01384422; GLPG0634-CL-201 | Galapagos NV |
| Filgotinib, adalimumab, placebo | PsA | 3 | Recruiting | International |
PENGUIN 1; NCT04115748; GS-US-431-4566; 2019-001996-35; JapicCTI-205202 |
Gilead Sciences |
| Filgotinib, placebo | PsA | 3 | Recruiting | International |
PENGUIN 2; NCT04115839; GS-US-431-4567; 2019-002021-29; JapicCTI-205201 |
Gilead Sciences |
| Filgotinib, placebo | PsA | 2 | Completed | International |
EQUATOR; NCT03101670; GLPG0634-CL-224 |
Galapagos NV |
| Filgotinib | PsA | 2 | Ongoing | International |
EQUATOR 2; NCT03320876; GLPG0634-CL-225; 2017-000545-52 |
Galapagos NV |
| Filgotinib, placebo | AS | 2 | Completed | International | TORTUGA; GLPG0634-CL-223 | Galapagos NV |
|
Filgotinib, placebo, SOC |
RA, PsA, AS, AxSp | 2 | Ongoing | International |
MANTA-Ray; NCT03926195; GLPG0634-CL-227; 2018-003933-14 |
Galapagos NV |
| Filgotinib, placebo | CD | 3 | Recruiting | International |
DIVERSITY; NCT02914561; GS-US-419-3895; 2016-001367-36 |
Gilead Sciences |
| Filgotinib, placebo | CD | 3 |
Enrolling by invitation |
International |
DIVERSITYLTE; NCT02914600; GS-US-419-3896; 2016-002763-34 |
Gilead Sciences |
| Filgotinib, placebo | CD | 2 | Completed | International |
NCT02048618; FITZROY; GLPG0634-CL-211; 2013-002857-32 |
Galapagos NV |
| Filgotinib, placebo | CD | 2 | Completed | International |
Divergence 1; NCT03046056; GS-US-419-4015; 2016-003179-23 |
Gilead Sciences |
| Filgotinib, placebo | CD | 2 | Ongoing | International |
Divergence 2; NCT03077412; GS-US-419-4016; 2016-003153-15 |
Gilead Sciences |
| Filgotinib, placebo | UC | 3 | Completed | International |
SELECTION; NCT02914522; GS-US-418-3898; 2016-001392-78 |
Gilead Sciences |
| Filgotinib, placebo | UC | 3 | Ongoing | International |
SELECTIONLTE; NCT02914535; GS-US-418-3899; 2016-002765-58 |
Gilead Sciences |
|
Filgotinib, placebo, SOC |
IBD | 2 | Ongoing | International |
MANTA; NCT03201445; GS-US-418-4279; 2017-000402-38 |
Gilead Sciences |
AS ankylosing spondylitis, AxSp non-radiographic axial spondyloarthritis, CD Crohn’s disease, csDMARD conventional synthetic disease-modifying antirheumatic drug; IBD inflammatory bowel disease, PsA psoriatic arthritis, RA rheumatoid arthritis, SOC standard of care, UC ulcerative colitis